Karyopharm Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jefferies Remains Sidelined on Karyopharm Therapeutics (KPTI) Following 4Q - PT to $10
March 15, 2016 8:39 AM EDTJefferies reiterated a Hold rating on Karyopharm Therapeutics (NASDAQ: KPTI), and cut the price target to $10.00 (from $14.00), following the company's 4Q earnings report. Total operating expenses for 4Q were $29.3M consisting of $24.1M of R&D vs. a $24.5M estimate and... More
Karyopharm Therapeutics (KPTI) Reports Q4 Loss of $0.81/Share
March 14, 2016 7:31 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.81), versus ($0.79) reported last year.
Based on current operating plans, Karyopharm expects that its existing cash and cash equivalents will fund its research and development programs and operations into the middle of 2018, including advancing the four... More
